PROSPECT: An Imaging Study in Patients With Unstable Atherosclerotic Lesions

Exclusion Criteria

• •1. Patient has had a documented acute ST-segment elevation myocardial infarction within the past 24 hours.
• •2. Known serum creatinine \> 2.5 mg/dl.
• •3. Decompensated hypotension or heart failure requiring intubation, inotropes, intravenous diuretics or intraaortic balloon counterpulsation.
• •4. Patient has a known hypersensitivity, allergy or contraindication to any of the following: aspirin, heparin, clopidogrel, and ticlopidine or to contrast that cannot be adequately pre-medicated.
• •5. Presence of cardiac implants (i.e. implantable defibrillators); however, prior implantation of pacemaker or biventricular pacemaker is permitted.
• •6. Presence of cardiogenic shock.
• •7. Patient has a known left ventricular ejection fraction \<30%.
• •8. Refractory ventricular arrhythmia requiring either intravenous pharmacologic treatment or defibrillator therapy (e.g. ventricular tachycardia or fibrillation).
• •9. Acute conduction system disease requiring temporary pacemaker insertion.
• •10. Patient has had a recent (within 6 months) PCI unless the patient is undergoing a staged procedure for dual vessel treatment.
• •11. Patient has other medical illness (i.e., cancer or congestive heart failure) or recent history of substance abuse that may cause non-compliance with the Investigational Plan, confound the data interpretation or is associated with an anticipated limited life expectancy less than one year..
• •12. Prior participation in this study or patient is currently enrolled in another investigational use device or drug study that has not reached its primary endpoint. If the patient is enrolled in another study that is not investigational, required visits for that trial must not interfere with the conduct of this trial.